Human umbilical cord blood-derived mesenchymal stromal cells display a novel interaction between P-selectin and galectin-1

Scandinavian Journal of Immunology

Volumn 80, Issue 1, 2014, Pages 12-21

  Suila, H ^a   Hirvonen, T ^a   Kotovuori, A ^a   Ritamo, I ^a   Kerkela E ^a   Anderson, H ^a   Natunen, S ^a   Tuimala, J ^a   Laitinen, S ^a   Nystedt, J ^a   Rabina J ^a   Valmu, L ^a  

^a FINNISH RED CROSS BLOOD SERVICE   (Finland)

Author keywords

[No Author keywords available]

Indexed keywords

GALECTIN 1; P SELECTIN GLYCOPROTEIN LIGAND 1; PADGEM PROTEIN; SIALYL LEWIS X ANTIGEN;

ARTICLE; CHEMICAL ANALYSIS; HUMAN; HUMAN CELL; IMMUNOMODULATION; IMMUNOSUPPRESSIVE TREATMENT; MESENCHYMAL STROMA CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN INTERACTION; UMBILICAL CORD BLOOD;

FETAL BLOOD; GALECTIN 1; HUMANS; MEMBRANE GLYCOPROTEINS; MESENCHYMAL STROMAL CELLS; OLIGOSACCHARIDES; P-SELECTIN;

EID: 84902688084     PISSN: 03009475     EISSN: 13653083     Source Type: Journal    
DOI: 10.1111/sji.12179     Document Type: Article

References (58)

1. Yagi H, Soto-Gutierrez A, Parekkadan B et al. Mesenchymal stem cells: mechanisms of immunomodulation and homing. Cell Transplant 2010;19:667-79.
2. Keating A. Mesenchymal stromal cells: new directions. Cell Stem Cell 2012;10:709-16.
3. Salem HK, Thiemermann C. Mesenchymal stromal cells: current understanding and clinical status. Stem Cells 2010;28:585-96.
4. Uccelli A, Moretta L, Pistoia V. Mesenchymal stem cells in health and disease. Nat Rev Immunol 2008;8:726-36.
5. La Rocca G, Corrao S, Lo Iacono M, Corsello T, Farina F, Anzalone R. Novel immunomodulatory markers expressed by human WJ-MSC: an updated review in regenerative and reparative medicine. Open Tissue Eng Regen Med J 2012;5:50-8.
6. La Rocca G, Lo Iacono M, Corsello T, Corrao S, Farina F, Anzalone R. Human Wharton's jelly mesenchymal stem cells maintain the expression of key immunomodulatory molecules when subjected to osteogenic, adipogenic and chondrogenic differentiation in vitro: new perspectives for cellular therapy. Curr Stem Cell Res Ther 2013;8:100-13.
7. Ren G, Chen X, Dong F et al. Concise review: mesenchymal stem cells and translational medicine: emerging issues. Stem Cells Transl Med 2012;1:51-8.
8. Castillo-Melendez M, Yawno T, Jenkin G, Miller SL. Stem cell therapy to protect and repair the developing brain: a review of mechanisms of action of cord blood and amnion epithelial derived cells. Front Neurosci 2013;7:194.
9. Lu LL, Liu YJ, Yang SG et al. Isolation and characterization of human umbilical cord mesenchymal stem cells with hematopoiesis-supportive function and other potentials. Haematologica 2006;91:1017-26.
10. Kern S, Eichler H, Stoeve J, Kluter H, Bieback K. Comparative analysis of mesenchymal stem cells from bone marrow, umbilical cord blood, or adipose tissue. Stem Cells 2006;24:1294-301.
11. Gao J, Dennis JE, Muzic RF, Lundberg M, Caplan AI. The dynamic in vivo distribution of bone marrow-derived mesenchymal stem cells after infusion. Cells Tissues Organs 2001;169:12-20.
12. Schrepfer S, Deuse T, Reichenspurner H, Fischbein MP, Robbins RC, Pelletier MP. Stem cell transplantation: the lung barrier. Transplant Proc 2007;39:573-6.
13. Nystedt J, Anderson H, Tikkanen J et al. Cell surface structures influence lung clearance rate of systemically infused mesenchymal stromal cells. Stem Cells 2012;31:317-26.
14. Ankrum J, Karp JM. Mesenchymal stem cell therapy: two steps forward, one step back. Trends Mol Med 2010;16:203-9.
15. Caplan AI, Correa D. The MSC: an injury drugstore. Cell Stem Cell 2011;9:11-5.
16. Bernardo ME, Pagliara D, Locatelli F. Mesenchymal stromal cell therapy: a revolution in regenerative medicine? Bone Marrow Transplant 2012;47:164-71.
17. Henschler R, Deak E, Seifried E. Homing of mesenchymal stem cells. Transfus Med Hemother 2008;35:306-12.
18. Varki A. Selectin ligands. Proc Natl Acad Sci U S A 1994;91:7390-7.
19. Lasky LA. Selectins: interpreters of cell-specific carbohydrate information during inflammation. Science 1992;258:964-9.
20. Geng JG, Chen M, Chou KC. P-selectin cell adhesion molecule in inflammation, thrombosis, cancer growth and metastasis. Curr Med Chem 2004;11:2153-60.
21. Feuerhake F, Fuchsl G, Bals R, Welsch U. Expression of inducible cell adhesion molecules in the normal human lung: immunohistochemical study of their distribution in pulmonary blood vessels. Histochem Cell Biol 1998;110:387-94.
22. Moore KL, Stults NL, Diaz S et al. Identification of a specific glycoprotein ligand for P-selectin (CD62) on myeloid cells. J Cell Biol 1992;118:445-56.
23. Norgard KE, Moore KL, Diaz S et al. Characterization of a specific ligand for P-selectin on myeloid cells. A minor glycoprotein with sialylated O-linked oligosaccharides. J Biol Chem 1993;268:12764-74.
24. Leppanen A, White SP, Helin J, McEver RP, Cummings RD. Binding of glycosulfopeptides to P-selectin requires stereospecific contributions of individual tyrosine sulfate and sugar residues. J Biol Chem 2000;275:39569-78.
25. Ruster B, Gottig S, Ludwig RJ et al. Mesenchymal stem cells display coordinated rolling and adhesion behavior on endothelial cells. Blood 2006;108:3938-44.
26. Yilmaz G, Vital S, Yilmaz CE, Stokes KY, Alexander JS, Granger DN. Selectin-mediated recruitment of bone marrow stromal cells in the postischemic cerebral microvasculature. Stroke 2011;42:806-11.
27. Heiskanen A, Hirvonen T, Salo H et al. Glycomics of bone marrow-derived mesenchymal stem cells can be used to evaluate their cellular differentiation stage. Glycoconj J 2009;26:367-84.
28. Malviya G, Galli F, Sonni I, Pacilio M, Signore A. Targeting T and B lymphocytes with radiolabelled antibodies for diagnostic and therapeutic applications. Q J Nucl Med Mol Imaging 2010;54:654-76.
29. Sackstein R. Glycosyltransferase-programmed stereosubstitution (GPS) to create HCELL: engineering a roadmap for cell migration. Immunol Rev 2009;230:51-74.
30. Xia L, McDaniel JM, Yago T, Doeden A, McEver RP. Surface fucosylation of human cord blood cells augments binding to P-selectin and E-selectin and enhances engraftment in bone marrow. Blood 2004;104:3091-6.
31. Karp JM, Leng Teo GS. Mesenchymal stem cell homing: the devil is in the details. Cell Stem Cell 2009;4:206-16.
32. Kekarainen T, Mannelin S, Laine J, Jaatinen T. Optimization of immunomagnetic separation for cord blood-derived hematopoietic stem cells. BMC Cell Biol 2006;7:30.
33. Laitinen A, Nystedt J, Laitinen S. The isolation and culture of human cord blood-derived mesenchymal stem cells under hypoxic conditions. In: Vemuri M, Chase LG, Rao MS, eds. Mesenchymal Stem Cell Assays and Applications. New York: Humana Press, 2011: 63-73. ISBN 978-1-60761-998-7.
34. Dominici M, Le Blanc K, Mueller I et al. Minimal criteria for defining multipotent mesenchymal stromal cells. The International Society for Cellular Therapy position statement. Cytotherapy 2006;8:315-7.
35. Suila H, Pitkanen V, Hirvonen T et al. Are globoseries glycosphingolipids SSEA-3 and -4 markers for stem cells derived from human umbilical cord blood? J Mol Cell Biol 2010;3:99-107.
36. Karagianni M, Brinkmann I, Kinzebach S et al. A comparative analysis of the adipogenic potential in human mesenchymal stromal cells from cord blood and other sources. Cytotherapy 2013;15:76-88.
37. Hirvonen T, Suila H, Kotovuori A et al. The i blood group antigen as a marker for umbilical cord blood-derived mesenchymal stem cells. Stem Cells Dev 2012;21:455-64.
38. Natunen S, Lampinen M, Suila H et al. Metabolic glycoengineering of mesenchymal stromal cells with N-propanoylmannosamine. Glycobiology 2013;23:1004-12.
39. Kerkelä E, Hakkarainen T, Mäkelä T et al. Transient proteolytic modification of mesenchymal stromal cells increases lung clearance rate and targeting to injured tissue. Stem Cells Transl Med 2013;2:510-20.
40. Walcheck B, Leppanen A, Cummings RD et al. The monoclonal antibody CHO-131 binds to a core 2 O-glycan terminated with sialyl-Lewis x, which is a functional glycan ligand for P-selectin. Blood 2002;99:4063-9.
41. Rabilloud T, Carpentier G, Tarroux P. Improvement and simplification of low-background silver staining of proteins by using sodium dithionite. Electrophoresis 1988;9:288-91.
42. Shevchenko A, Wilm M, Vorm O, Mann M. Mass spectrometric sequencing of proteins silver-stained polyacrylamide gels. Anal Chem 1996;68:850-8.
43. R Core Team. R: A Language and Environment for Statistical Computing. Vienna, Austria: R Foundation for Statistical Computing. ISBN 3-900051-07-0, URL http://www.R-project.org/, 2012.
44. Dai M, Wang P, Boyd AD et al. Evolving gene/transcript definitions significantly alter the interpretation of GeneChip data. Nucleic Acids Res 2005;33:e175.
45. Dai M, Wang P, Jakupovic E, Watson SJ, Meng F. Web-based GeneChip analysis system for large-scale collaborative projects. Bioinformatics 2007;23:2185-7.
46. Scheurer SB, Roesli C, Neri D, Elia G. A comparison of different biotinylation reagents, tryptic digestion procedures, and mass spectrometric techniques for 2-D peptide mapping of membrane proteins. Proteomics 2005;5:3035-9.
47. Kinter M, Sherman NE. Protein Sequencing and Identification Using Tandem Mass Spectrometry. In: Kinter M, Sherman NE, eds. Protein Sequencing and Identification Using Tandem Mass Spectrometry. New York: John Wiley & Sons Inc, 2000:160-3. ISBN 0-471-32249-07.
48. Gieseke F, Bohringer J, Bussolari R, Dominici M, Handgretinger R, Muller I. Human multipotent mesenchymal stromal cells use galectin-1 to inhibit immune effector cells. Blood 2010;116:3770-9.
49. Sioud M. New insights into mesenchymal stromal cell-mediated T-cell suppression through galectins. Scand J Immunol 2011;73:79-84.
50. Lepelletier Y, Lecourt S, Renand A et al. Galectin-1 and semaphorin-3A are two soluble factors conferring T-cell immunosuppression to bone marrow mesenchymal stem cell. Stem Cells Dev 2010;19:1075-9.
51. Choudhary C, Kumar C, Gnad F et al. Lysine acetylation targets protein complexes and co-regulates major cellular functions. Science 2009;325:834-40.
52. Atoui R, Chiu RC. Concise review: immunomodulatory properties of mesenchymal stem cells in cellular transplantation: update, controversies, and unknowns. Stem Cells Transl Med 2012;1:200-5.
53. Najar M, Raicevic G, Id Boufker H et al. Modulated expression of adhesion molecules and galectin-1: role during mesenchymal stromal cell immunoregulatory functions. Exp Hematol 2010;38:922-32.
54. Leppanen A, Stowell S, Blixt O, Cummings RD. Dimeric galectin-1 binds with high affinity to alpha2, 3-sialylated and non-sialylated terminal N-acetyllactosamine units on surface-bound extended glycans. J Biol Chem 2005;280:5549-62.
55. Kadoya T, Horie H. Structural and functional studies of galectin-1: a novel axonal regeneration-promoting activity for oxidized galectin-1. Curr Drug Targets 2005;6:375-83.
56. Rabinovich GA, Toscano MA. Turning 'sweet' on immunity: galectin-glycan interactions in immune tolerance and inflammation. Nat Rev Immunol 2009;9:338-52.
57. Grigorian A, Torossian S, Demetriou M. T-cell growth, cell surface organization, and the galectin-glycoprotein lattice. Immunol Rev 2009;230:232-46.
58. Camby I, Le Mercier M, Lefranc F, Kiss R. Galectin-1: a small protein with major functions. Glycobiology 2006;16:137R-57R.